Terkko Navigator / Clinical Pharmacokinetics

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited

An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions

Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass

Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease

A Preterm Physiologically Based Pharmacokinetic Model. Part I: Physiological Parameters and Model Building

Update on Therapeutic Protein–Drug Interaction: Information in Labeling

Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses

Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus

Comment on:“Levothyrox ® New and Old Formulations: Are they Switchable for Millions of Patients?”

Authors’ Reply to Lechat et al.: “Levothyrox ® New and Old Formulations: Are they Switchable for Millions of Patients?”

Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review

Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate® ): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup

Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?

Population Pharmacokinetics of Apalutamide and its Active Metabolite N -Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects

Pharmacokinetics and Target Attainment of Antibiotics in Critically Ill Children: A Systematic Review of Current Literature

Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine

Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma

Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis

Correction to: Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study

Author’s Reply to Trechot: “Comment on Levothyrox ® New and Old Formulations: Are they Switchable for Millions of Patients?”

Authors’ Reply to Castello-Bridoux et al.: “Comment on Levothyrox ® New and Old Formulations: Are they Switchable for Millions of Patients?”

Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?

Comment on“Levothyrox ® New and Old Formulations: Are They Switchable for Millions of Patients?”

Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure–Response Relationships

Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children

Authors’ Reply to Nicolas: “Levothyrox ® New and Old Formulations: Are they Switchable for Millions of Patients?”

Comment on:“Levothyrox ® New and Old Formulations: Are they Switchable for Millions of Patients?”

Comment on:“Levothyrox ® New and Old Formulations: Are they Switchable for Millions of Patients?”

Authors’ Reply to Coste et al.: “Levothyrox ® New and Old Formulations: Are they Switchable for Millions of Patients?”

Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis

Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures

Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline

Comment on“Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients”

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

A Quantitative Enterohepatic Circulation Model: Development and Evaluation with Tesofensine and Meloxicam

Use of Target Controlled Infusion to Derive Age and Gender Covariates for Propofol Clearance

Clinical Pharmacokinetics of Atypical Antipsychotics: A Critical Review of the Relationship Between Plasma Concentrations and Clinical Response

The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs: Pharmacokinetic and Therapeutic Implications

Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling